Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

BACKGROUND: Treatment de-escalation in early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has been attempted in order to decrease costs and toxicities. One of the strategies pursued is decreasing trastuzumab treatment duration, with mixed results thus far. Trast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Eiger, Daniel, Franzoi, Maria Alice, Pondé, Noam, Brandão, Mariana, de Angelis, Claudia, Schmitt Nogueira, Melanie, de Hemptinne, Quentin, de Azambuja, Evandro
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7046387/
https://ncbi.nlm.nih.gov/pubmed/32079624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000659
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados